These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 39323385)

  • 1. Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A.
    Yada K; Nogami K
    Expert Opin Drug Metab Toxicol; 2024 Oct; ():1-10. PubMed ID: 39323385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA
    Expert Rev Hematol; 2023; 16(8):567-573. PubMed ID: 37289594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.
    Dargaud Y; Leuci A; Ruiz AR; Lacroix-Desmazes S
    Haematologica; 2024 Aug; 109(8):2436-2444. PubMed ID: 38356459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
    J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
    Lissitchkov T; Willemze A; Katragadda S; Rice K; Poloskey S; Benson C
    Blood Adv; 2022 Feb; 6(4):1089-1094. PubMed ID: 34794179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
    Lissitchkov T; Willemze A; Jan C; Zilberstein M; Katragadda S
    Res Pract Thromb Haemost; 2023 May; 7(4):100176. PubMed ID: 37538505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
    Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
    Ryu JH; Bauer KA; Schulman S
    J Thromb Haemost; 2023 Dec; 21(12):3508-3510. PubMed ID: 37734716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
    N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efanesoctocog Alfa: First Approval.
    Keam SJ
    Drugs; 2023 May; 83(7):633-638. PubMed ID: 37022666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.
    Fuller JR; Knockenhauer KE; Leksa NC; Peters RT; Batchelor JD
    Blood; 2021 May; 137(21):2970-2980. PubMed ID: 33569592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L; Peyvandi F; Chan AKC; Königs C; Zulfikar B; Yuan H; Simpson M; Álvarez Román MT; Carcao M; Staber JM; Dunn AL; Chou SC; d'Oiron R; Albisetti M; Demissie M; Santagostino E; Yarramaneni A; Wong N; Abad-Franch L; Gunawardena S; Fijnvandraat K;
    N Engl J Med; 2024 Jul; 391(3):235-246. PubMed ID: 39018533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.
    Yee A; Gildersleeve RD; Gu S; Kretz CA; McGee BM; Carr KM; Pipe SW; Ginsburg D
    Blood; 2014 Jul; 124(3):445-52. PubMed ID: 24850761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind.
    Hermans C; Pierce GF
    J Thromb Haemost; 2024 Jul; 22(7):1844-1846. PubMed ID: 38679336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII.
    Chia J; Pestel S; Glauser I; Emmrich K; Hardy MP; Mischnik M; Raquet E; Tomasetig V; Claar P; Zalewski A; Bass GT; Turnbull V; Chen CG; Wilson MJ; Panousis C; Weimer T; Andrews A; Verhagen AM; Dower SK
    J Thromb Haemost; 2021 Nov; 19(11):2710-2725. PubMed ID: 34333849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
    Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
    Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.